This authoritative management report from New Drug Discovery and Scrip Reports will help you develop a viable technology strategy. Although investment in genomics alone runs into billions of dollars every year, this and other related drug discovery technologies have yet to bear fruit. Part of the problem lies in the flood of information which hampers senior executives in their strategy development.
Data to Drugs: Strategies for Benefiting from the New Drug Discovery Technologies explains the technologies, identifies short- and long-term commercial opportunities and assesses the companies at the cutting edge of drug discovery technology. It provides consultancy-level advice, guidance and analysis on every aspect of the technology-business interface.
It six in-depth sections the report equips you with a powerful set of insights into how best to manage technology and information. The analysis ranges from the technical challenges that remain to be solved using genomics and related technologies to their market impact, particularly the fruition of pharmacogenomics efforts.
Price: £995/$1,995/¥239,000
Ref: BS1015E
Pages: 160+
Published: July 1999
Table of Contents
List of Tables
List of Figures
About the Authors
Introduction
Facing the Future
What the New Technologies Offer
Overcoming Technological Limitations
Decision Points: Where Do We Go from Here?
Gaining a Strategic Edge
Chapter 1: The Continuing Revolution in Drug Discovery Technologies
Impact of New Drug Discovery Techniques
New Products
New Competitors
A New Suite of Complementary Platform Technologies
Genomics
Combinatorial Chemistry and High-Throughput
Screening
Bioinformatics
Functional Genomics
Proteomics
Pharmacogenomics
Changing Technical and Competitive Landscape
The Promise
The Challenge
Why the Need for New Technologies?
Economic Hurdles
The "Innovation Deficit"
Limitations of Traditional Drug Discovery
Technologies
Potential of New Technologies
Medical Breakthroughs
Market Potential
Current/Near-Term Products
Chapter 2: Gaining Access to New Technologies
Alternative Strategies for Bringing in New Technology
In-House Development
Discovery by In-House Scientists
Adaptation from Outside Sources
Partnerships with Academia
Partnerships with Smaller Technology Companies
Corporate Acquisitions
Organizing to Gain Access to New Technologies
Chapter 3: Technical Problems in Getting Results
Too Much Data, Not Enough Knowledge
Bridging the Gap between Data and Information
The Role of Bioinformatics
Uses of Bioinformatics
Requirements for Bioinformatics
Core Competencies
Critical Success Factors
Challenges
Getting from Sequences to Targets
The Lengthening Drug Discovery Pathway
Traditional and Evolving Technology
Structural Biology
Functional Genomics and Gene Chips
High-Throughput Screening
The Challenge of Genomics: So Many Targets, So Little Time
Chapter 4: Combinatorial Chemistry: Current Limitations, Future Promise
Current Issues
Use in High-Throughput Screening
Use in "Gene to Screen"
Need for Refinement
Types of Combinatorial Chemistry
Natural Products
Solid Phase Synthesis
Solution Phase Synthesis
Problems Associated with Combinatorial Chemistry
Purity and Structural Identification
Library Size and Differentiation
Hit-or-Miss Lead Generation
Solving the Diversity Dilemma
Computational Approaches
Redefining Diversity Space
New Approaches
Combinatorial Chemistry and the Genomics Challenge
Business Issues
New Directions
Chapter 5: Organizational and Strategic Challenges
Accessing and Assessing Outside Information
Information Sources
Sifting through the Deluge
Evaluating and Managing Partnerships
Partnership Objectives
Components for Integration: Build versus Buy
Dealing with Cultural and Size Differences
Partnerships with Biotech
Partnerships with Academia
Boosting R&D Innovation
The Cultural Challenge
The Impact of Mergers
Major Market Changes
Pharmacogenomics and Market Fragmentation
Curing Disease through Gene Therapy
Chapter 6: The New Frontier
Moving Toward Technological Solutions
Handling Raw Genomics Data
Academic Institutions
Industrial Sources
Identifying Disease-Causing Genes
Discovering New Drug Entities
SME Technology
LME Technology
Maximizing the Commercial Potential of the New Drug Discovery Technologies
Moving Past the Quick Fix
Positioning for Success
What the Future Holds
List of Tables
Table 1-1 Financial Clout of Leading Biotech Competitors
Table 1-2 Selected Leading Companies and Other Organizations Developing Drug Discovery Platform Technologies
Table 1-3 Breakdown of Drugs Approved by the FDA, 1995-1998
Table 1-4 Genomics-Based Therapeutics Currently in Clinical Trials
Table 2-1 Benefits and Drawbacks of Various Strategies for Acquiring New Technologies
Table 2-2 Organizations Involved in the SNP Consortium
Table 2-3 Selected Recent Deals Involving Genomics, Functional Genomics, or Pharmacogenomics
Table 2-4 Selected Recent Deals Involving Combinatorial Chemistry and/or High-Throughput Screening
Table 3-1 Fully Sequenced Microbial Genomes
Table 3-2 Exemplary Software Programs for Bioinformatics
Table 3-3 Companies Developing Gene Chip Technologies
Table 4-1 Characteristics of Different Types of Combinatorial Chemistry
Table 4-2 Requirements for Combinatorial Chemistry to Meet the Genomics Challenge
Table 5-1 Key Areas of Need for Timely Information
Table 5-2 Challenges in Gaining Timely Access to Critical Outside Information
Table 5-3 Sources of Information on Drug Discovery
Table 5-4 Goals of Partnerships with Biotech Companies and Academic Groups
Table 5-5 Key Factors in Make-or-Buy Decisions for Technology Platforms
Table 5-6 Big Pharma-Biotech Divisions That Can Affect the Success of Partnerships
Table 5-7 Pharmaceutical Satellite Laboratories in the Boston Area
Table 6-1 Interdisciplinary Life Science Centers Being Established by Academic Institutions
Table 6-2 Strategies for Bypassing the Limitations of Genomics and Molecular Diversity Technologies
Table 6-3 The Gap between Technology and Therapeutics: Small Molecule Drugs
Table 6-4 The Gap between Technology and Therapeutics: Protein Drugs
List of Figures
Figure 1-1 Transforming Effects of Biotechnology on the Pharmaceutical Industry of the 1980s
Figure 1-2 Role of Various Platform Technologies in the Genomics-Led Drug Discovery Process
Figure 1-3 Pre-Genomics Methods of Discovering New Leads
Figure 1-4 Pre-Genomics Sources of Potential New Drugs
Figure 1-5 Selected Patient Populations Targeted by Genomics-Based Therapies, 2005-2020
Figure 1-6 Market Potential of Genomics-Based Therapies for Selected Indications, 2005-2020
Figure 3-1 Investment Required for Different Stages in the Drug Discovery Pathway
Figure 3-2 Role of Bioinformatics in Linking Molecular Biology, Target Identification and Drug Discovery, and Computational Science
Figure 3-3 The Effect of Integrated Bioinformatics on Drug Discovery
Figure 3-4 The Traditional Drug Discovery Pathway
Figure 3-5 Reverse Integration in Drug Discovery
Figure 3-6 The Gene Chip Process
Figure 4-1 Current Pathway for Drug Discovery
Figure 4-2 Compressed Drug Discovery Process through Use of Chemical Ligands
Figure 4-3 Core and Building Block Assembly of Combinatorial Mixtures
Figure 4-4 Drug Diversity Space Based on Known Drugs
Figure 4-5 Proteomal Diversity Space: Beyond Current Drug Diversity Space
Figure 5-1 Moving from Information to Action MORPACE Pharma Group, Ltd.
© PJB Publications Ltd. 2000 All rights reserved. |